McGuire Investment Group LLC Decreases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

McGuire Investment Group LLC trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.2% in the 4th quarter, Holdings Channel reports. The institutional investor owned 59,413 shares of the medical research company’s stock after selling 115 shares during the quarter. IQVIA accounts for 1.7% of McGuire Investment Group LLC’s investment portfolio, making the stock its 23rd largest holding. McGuire Investment Group LLC’s holdings in IQVIA were worth $11,675,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Exchange Traded Concepts LLC raised its holdings in shares of IQVIA by 18.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 5,209 shares of the medical research company’s stock worth $1,024,000 after buying an additional 821 shares during the period. Brighton Jones LLC increased its stake in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the period. Mutual Advisors LLC lifted its position in shares of IQVIA by 14.8% during the fourth quarter. Mutual Advisors LLC now owns 1,689 shares of the medical research company’s stock worth $334,000 after purchasing an additional 218 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of IQVIA by 3.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 36,512 shares of the medical research company’s stock valued at $7,175,000 after purchasing an additional 1,172 shares during the period. Finally, Advisory Alpha LLC grew its holdings in shares of IQVIA by 18.2% in the fourth quarter. Advisory Alpha LLC now owns 3,189 shares of the medical research company’s stock worth $627,000 after purchasing an additional 492 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Truist Financial decreased their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Stephens started coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price on the stock. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Redburn Atlantic assumed coverage on IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $204.54 on Friday. The business’s 50 day moving average price is $199.47 and its 200-day moving average price is $221.09. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market capitalization of $37.12 billion, a PE ratio of 26.84, a P/E/G ratio of 2.14 and a beta of 1.48.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.